who likes 53c?

Received this 5minutes ago. Senior Analyst at Ords I believe. Hope it's not breaching any copyright.

Subject: Prima BioMed Limited (PRR - Buy / High risk) - Initiation of Coverage



Prima BioMed Limited (PRR)
Buy / High risk
Valuation: $0.53 / Last Price: $0.28

Developing the CVac vaccine for ovarian cancer

? Prima Biomed Limited (PRR) is a biotechnology company with a focus on technologies in the fields of cancer immunotherapy and immunology. It is developing a vaccine known as CVac to treat ovarian cancer and has assembled an experienced and well-regarded team to oversee the development process.

? There is a large, unmet market need in ovarian cancer treatment, and CVac is being developed to meet this need. The company has a clear strategy to develop and commercialise CVac over the next three to five years, with opportunities to expand the scope of the treatment to other types of cancer.

? A Phase III clinical trial will commence in 3Q11. It aims to recruit 800 patients and will be a pivotal study of CVac. If the trial is successful regulatory approvals will follow. OML believes that CVac, if successful, can achieve ?blockbuster? status (sales of $1 billion or more per annum), and at current prices offers an excellent opportunity to participate in this highly prospective and locally developed oncology treatment.

? Catalysts for the stock over the next 18-24 months include: 1) completion of Phase IIb recruitment (expected by 3Q11), 2) German/EU manufacturing approval (Q311), 3) completion of Phase III trial recruitment (expected by 4Q12), and 4) indicative results of the Phase IIb trial (expected by Q312). Key risks for CVac include: 1) a lack of efficacy, given the treatment is yet to be tested on a large population, 2) difficulty in scaling the manufacturing procedures, and 3) delays in the clinical trials imposed by regulatory bodies.

? OML initiates coverage with a Buy recommendation and a risk-adjusted valuation of $0.53 per share. If the data plays out favourably, we believe PRR is materially undervalued and that this value will be unlocked progressively over the coming years.